A Groundbreaking Collaboration to Combat Dementia

In a game-changing move for Alzheimer's disease research, South Korea's innovative AI startup, Neurophet, has joined forces with the International Registry for Alzheimer's Disease and Other Dementias Foundation (InRAD). This collaboration, formalized through a Memorandum of Understanding (MoU), aims to standardize data related to Alzheimer's and dementia on a global scale.

Transforming Real-World Data Into Actionable Insights

The partnership is set to bolster the development of harmonized standards for real-world data on Alzheimer's disease and other dementias. By facilitating the integration of AI-driven neuroimaging technologies into existing data ecosystems, Neurophet and InRAD are breaking down major barriers that hinder evidence generation in this critical field.

Key Initiatives to Enhance Clinical Practice

Their ambitious agenda includes several key initiatives to revolutionize clinical workflows: enhancing MRI and PET analysis processes, aggregating clinical imaging and quantitative data, validating AI-based analysis tools, and launching joint research and educational programs designed to empower healthcare professionals.

Powerful Tools at Their Disposal

Neurophet will leverage its cutting-edge products in this collaboration, including: - **Neurophet AQUA AD**: An advanced software solution for monitoring treatment effects and side effects in Alzheimer's patients. - **Neurophet SCALE PET**: A specialized tool for quantitative analysis of PET images. - **Neurophet AQUA**: A comprehensive brain MRI analysis software.

What InRAD Brings to the Table

InRAD operates a free registry that collects real-world data to improve understanding and management of Alzheimer's disease and other dementias. Coordinated by a non-profit entity based in the Netherlands, this registry will launch in 2025, featuring a secure, Azure cloud-based platform that complies with regional governance requirements.

A Future of Improved Dementia Care Awaits

This partnership between Neurophet and InRAD not only paves the way for enriched data standards but also promises to enhance the everyday clinical practice of managing Alzheimer's and dementia, ultimately leading to better patient outcomes and transformative changes in healthcare.